Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand will present at the BIO CEO and Investor Conference on Monday, ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Nishan de Silva, M.D., as Vice President of Corporate Development. In this newly created position, Dr. de Silva will ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its fourth quarter 2011 earnings release will be issued after market close on Tuesday, February 7, 2012. Ligand’s President and ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand, will present at the Biotech Showcase 2012 Conference on Tuesday, ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into platform Captisol® license and supply agreements with Eli Lilly and Company in undisclosed therapeutic ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand, will present at the Oppenheimer 22nd Annual Healthcare ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the “Company” or “Ligand”) today announced financial results for the three and nine months ended September 30, 2011 and provided a business update. ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from preclinical studies on its Interleukin-1 Receptor Associated Kinase-4 (IRAK4) program was featured in an oral ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced data from the Phase II study with its Captisol-enabled®, propylene glycol-free (PG-free) melphalan. ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2011 financial results on Tuesday, November 8, 2011. Ligand’s President and CEO, John Higgins, Executive ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a global licensing agreement with Chiva Pharmaceuticals, Inc. for Fablyn (lasofoxifene), a selective estrogen ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand will present at the BioCentury NewsMakers Conference on Friday, October ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that Senior Director of Business Development and Investor Relations, Rob McKay will present at the Stifel Nicolaus Healthcare ... read more